2026 Cardiology Grand Rounds | Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy

November 4, 2026

Transthyretin amyloidosis (ATTR) is a massively under-recognized disease, and its symptoms are not very specific. Patients may go years without diagnosis, as this disease is often hiding within other more common syndromes. It is imperative to improve recognition of diagnosis and treatment of this condition, which may go undetected by healthcare providers.  

Increased diagnosis of Transthyretin amyloidosis (ATTR) will improve morbidity and mortality.  There are multiple effective emerging treatment strategies. Population-based analyses and systematic reviews demonstrate that diagnosed prevalence is considerably lower than expected from prospective screening studies, which identify ATTR-CM in approximately 10–15% of several high-risk populations (e.g., older adults with HFpEF, unexplained LV hypertrophy, or severe aortic stenosis). These findings support a significant gap in disease recognition and underscore the need for increased clinician awareness and earlier diagnostic evaluation. 

Target Audience

Healthcare providers.

Learning Objectives

  • Identify red flag symptoms of transthyretin amyloidosis (ATTR).
  • Discuss the treatment options for ATTR.
  • Outline the diagnostic pathway for the confirmation of ATTR.
  • Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2026 Cardiology Grand Rounds | Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
11/04/2026
Activity expires: 
11/05/2026
Event starts: 
11/04/2026 - 12:00pm PST
Event ends: 
11/04/2026 - 1:00pm PST
Add to calendar: 
City of Hope | Virtual

Virtual Meeting- Zoom

Faizi A. Jamal, MD, FACC  Chief, Division of Cardiology; Director, Non-Invasive Cardiology Laboratory; Associate Clinical Professor, Department of Medicine; City of Hope

Presenter: Dr. Jamal has indicated the following relevant financial relationships: Consultant for Alnylam Pharmaceuticals, and Ultromics. 

The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.

CME Committee/Reviewer no relevant financial relationships:  Daneng Li, MD

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2026 Cardiology Grand Rounds | Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.